Rehabilitation program of post-COVID-19 syndrome with the use of nitric oxide and molecular hydrogen

Cover Page

Cite item

Full Text

Abstract

Рost-COVID-19 syndrome (PS) is one of the medical and social problem. According to WHO, 10–20% of COVID-19 patients suffer from PS. The use of medical gases – inhaled nitric oxide (iNO) and molecular hydrogen (iH2) – may influence on the mechanisms of development PC.

Aim. To evaluate the safety and efficacy of the combined inhalation of NO and H2 (iNO/iH2) in patients with respiratory manifestations of PS.

Materials and methods. 34 patients with PS (11 men/23 women, 60.0±11.7 years) were included in the prospective open-label controlled study in parallel groups: the main group (n=17) received iNO/iH2 for 90 minutes once a day for 10 days (concentration of NO 60 ppm, H2<4% in the gas mixture), the control group (n=17) didn’t receive inhalations. The period from the confirmation of COVID-19 to the start of the study was 641.8±230.5 days. The groups did not differ in the baseline parameters. The clinical symptoms (from the self-observation diary and mMRC questionnaires, "dyspnea language"), FAS, HADS, SF-36 scores, 6-minute walk test, the blood serum parameters of oxidative stress, the dynamics of the microcirculation in the eye bulbar conjunctiva were evaluated. The individual dose of iNO has chosen during a 15-minute test (the positive dynamics of the microcirculation have indicated that the dose was selected correctly).

Results. The decrease the symptoms severity, such as dyspnea, cough, fatigue and palpitations (p<0.005), the increase in SF-36 questionnaire scores (p=0.006) and a reducing of FAS score (p=0.001), as well as the anxiety component of HADS (p=0.02) were revealed at the end of treatment in the main group compared to the control group. We observed an improvement in distance walked (p=0.01) and the values SpO2 (p=0.04) in 6-minute walk test, the increase in the volumetric blood flow velocity in venules (p<0.001), and the date in oxidative damage (p<0.001) and antioxidant activity (p=0.03) parameters in the blood serum.

Conclusion. The results of the study demonstrate clinical efficacy iNO/iH2 on clinical indicators, parameters of oxidative stress and microcirculation in patients with PS.

About the authors

Darya D. Pozdnyakova

Pirogov Russian National Research Medical University

Author for correspondence.
Email: daryapozdn@yandex.ru
ORCID iD: 0000-0002-7410-4297

ассистент, аспирант каф. госпитальной терапии педиатрического фак-та ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»

Russian Federation, Moscow

Tatiana А. Bakhareva

Pirogov Russian National Research Medical University

Email: baharevatatyana3@gmail.com
ORCID iD: 0000-0002-0206-6420

ординатор каф. госпитальной терапии педиатрического фак-та ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»

Russian Federation, Moscow

Irina A. Baranova

Pirogov Russian National Research Medical University

Email: iribaranova@yandex.ru
ORCID iD: 0000-0002-2469-7346

д-р мед. наук, проф. каф. госпитальной терапии педиатрического фак-та ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»

Russian Federation, Moscow

Victor D. Selemir

Russian Federal Nuclear Center – All-Russian Research Institute of Experimental Physics

Email: selemir@vniief.ru
ORCID iD: 0000-0001-7331-2679

д-р физ.-мат. наук, чл.-кор. РАН, зам. науч. рук. по электрофизическому направлению ФГУП РФЯЦ-ВНИИЭФ

Russian Federation, Sarov

Alexander G. Chuchalin

Pirogov Russian National Research Medical University

Email: pulmomoskva@mail.ru
ORCID iD: 0000-0002-6808-5528

акад. РАН, д-р мед. наук, проф., зав. каф. госпитальной терапии педиатрического фак-та ФГАОУ ВО «РНИМУ им. Н.И. Пирогова», председатель правления Российского респираторного общества

Russian Federation, Moscow

References

  1. Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-7. doi: 10.1016/S1473-3099(21)00703-9
  2. Коронавирусная инфекция (COVID-19): постковидный синдром. Режим доступа: https://www.who.int/ru/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition. Ссылка активна на 20.10.2023 [Koronavirusnaia infektsiia (COVID-19): postkovidnyi sindrom. Available at: https://www.who.int/ru/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition. Accessed: 20.10.2023 (in Russian)].
  3. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021;53(10):737-54. doi: 10.1080/23744235.2021.1924397
  4. Chen C, Haupert SR, Zimmermann L, et al. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226(9):1593-607. doi: 10.1093/infdis/jiac136
  5. Malik P, Patel K, Pinto C, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL) – A systematic review and meta-analysis. J Med Virol. 2022;94(1):253-62. doi: 10.1002/jmv.27309
  6. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-15. doi: 10.1038/s41591-021-01283-z
  7. Cumpstey AF, Clark AD, Santolini J, et al. COVID-19: A Redox Disease-What a Stress Pandemic Can Teach Us About Resilience and What We May Learn from the Reactive Species Interactome About Its Treatment. Antioxid Redox Signal. 2021;35(14):1226-68. doi: 10.1089/ars.2021.0017
  8. Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin. 2023;44(4):695-709. doi: 10.1038/s41401-022-00998-0
  9. Mikuteit M, Baskal S, Klawitter S, et al. Amino acids, post-translational modifications, nitric oxide, and oxidative stress in serum and urine of long COVID and ex COVID human subjects. Amino Acids. 2023;55(9):1173-88. doi: 10.1007/s00726-023-03305-1
  10. Sano M, Suzuki M, Homma K, et al. Promising novel therapy with hydrogen gas for emergency and critical care medicine. Acute Med Surg. 2018;5(2):113-8. doi: 10.1002/ams2.320
  11. Matei N, Camara R, Zhang JH. Emerging mechanisms and novel applications of hydrogen gas therapy. Med Gas Res. 2018;8(3):98-102. doi: 10.4103/2045-9912.239959
  12. Ge L, Yang M, Yang NN, et al. Molecular hydrogen: a preventive and therapeutic medical gas for various diseases. Oncotarget. 2017;8(60):102653-73. doi: 10.18632/oncotarget.21130
  13. Шогенова Л.В., Чыонг Тхи Тует, Крюкова Н.О., и др. Ингаляционный водород в реабилитационной программе медицинских работников, перенесших COVID-19. Кардиоваскулярная терапия и профилактика. 2021;20(6):2986 [Shogenova LV, Truong Thi Tuet, Kryukova N.O., et al. Hydrogen inhalation in rehabilitation program of the medical staff recovered from COVID-19. Cardiovascular Therapy and Prevention. 2021;20(6):2986 (in Russian)]. doi: 10.15829/1728-8800-2021-2986
  14. Botek M, Krejčí J, Valenta M, et al. Molecular Hydrogen Positively Affects Physical and Respiratory Function in Acute Post-COVID-19 Patients: A New Perspective in Rehabilitation. Int J Environ Res Public Health. 2022;19(4). doi: 10.3390/ijerph19041992
  15. Kamenshchikov NO, Berra L, Carroll RW. Therapeutic Effects of Inhaled Nitric Oxide Therapy in COVID-19 Patients. Biomedicines. 2022;10(2). doi: 10.3390/biomedicines10020369
  16. Alqahtani JS, Aldhahir AM, Al Ghamdi SS, et al. Inhaled Nitric Oxide for Clinical Management of COVID-19: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022;19(19). doi: 10.3390/ijerph191912803
  17. Shinbo T, Kokubo K, Sato Y, et al. Breathing nitric oxide plus hydrogen gas reduces ischemia-reperfusion injury and nitrotyrosine production in murine heart. Am J Physiol Heart Circ Physiol. 2013;305(4):H542-50. doi: 10.1152/ajpheart.00844.2012
  18. Liu H, Liang X, Wang D, et al. Combination therapy with nitric oxide and molecular hydrogen in a murine model of acute lung injury. Shock. 2015;43(5):504-11. doi: 10.1097/SHK.0000000000000316

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Schematic of the research protocol.

Download (109KB)

Copyright (c) 2024 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies